Bioatla Inc (BCAB)

$0.34 -0.01 (-3.74%)
Market Cap 17.08M
Revenue (ttm) 11.00M
Net Income (ttm) -69.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -634.36%
Debt to Equity Ratio 0.00
Volume 402,400
Avg Vol 780,938
Day's Range N/A - N/A
Shares Out 48.35M
Stochastic %K 60%
Beta 1.08
Analysts Strong Sell
Price Target $10.67

Latest News on BCAB

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 6:18 PM EDT - 6 days ago

BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

BioAtla Cuts 30% of Jobs in Restructuring Effort

Mar 27, 2025, 5:05 PM EDT - 6 days ago

BioAtla Cuts 30% of Jobs in Restructuring Effort

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

Mar 27, 2025, 4:05 PM EDT - 6 days ago

BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

Mar 20, 2025, 8:00 AM EDT - 13 days ago

BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

Mar 19, 2025, 8:00 AM EDT - 14 days ago

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

Mar 4, 2025, 7:34 AM EST - 4 weeks ago

AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Dec 20, 2024, 9:00 AM EST - 3 months ago

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 16, 2024, 8:00 AM EST - 3 months ago

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Dec 10, 2024, 8:00 AM EST - 4 months ago

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 8:53 AM EST - 5 months ago

BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 8, 2024, 6:12 AM EDT - 6 months ago

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

BioAtla: Numerous Catalysts Coming In Q4

Oct 7, 2024, 11:29 AM EDT - 6 months ago

BioAtla: Numerous Catalysts Coming In Q4

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 6 months ago

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

Oct 1, 2024, 8:00 AM EDT - 6 months ago

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Sep 23, 2024, 7:30 AM EDT - 6 months ago

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:32 AM EDT - 8 months ago

BioAtla, Inc. (BCAB) Q2 2024 Earnings Call Transcript

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

Jul 25, 2024, 5:39 PM EDT - 8 months ago

BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

BioAtla to Participate in the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 11 months ago

BioAtla to Participate in the Jefferies Global Healthcare Conference

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2024, 5:05 PM EDT - 11 months ago

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:35 PM EDT - 11 months ago

BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

May 14, 2024, 4:05 PM EDT - 11 months ago

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Participate in the Citizens JMP Life Sciences Conference

May 8, 2024, 8:00 AM EDT - 11 months ago

BioAtla to Participate in the Citizens JMP Life Sciences Conference

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

May 7, 2024, 8:00 AM EDT - 11 months ago

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

May 6, 2024, 8:00 AM EDT - 11 months ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 2, 2024, 10:03 AM EDT - 11 months ago

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 24, 2024, 4:35 PM EDT - 1 year ago

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:21 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q4 2023 Earnings Call Transcript

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Mar 26, 2024, 4:01 PM EDT - 1 year ago

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Mar 19, 2024, 8:00 AM EDT - 1 year ago

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 7, 2024, 8:00 AM EST - 1 year ago

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

Dec 13, 2023, 8:00 AM EST - 1 year ago

BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

Dec 6, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

Dec 5, 2023, 8:00 AM EST - 1 year ago

BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

Nov 30, 2023, 8:00 AM EST - 1 year ago

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

Nov 28, 2023, 8:00 AM EST - 1 year ago

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

Nov 12, 2023, 5:38 AM EST - 1 year ago

BioAtla, Inc. (BCAB) Q3 2023 Earnings Call Transcript

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Nov 7, 2023, 4:01 PM EST - 1 year ago

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla to Participate in the Jefferies London Healthcare Conference

Nov 6, 2023, 4:05 PM EST - 1 year ago

BioAtla to Participate in the Jefferies London Healthcare Conference

BioAtla's Jay M. Short, Ph.D.

Oct 12, 2023, 7:30 AM EDT - 1 year ago

BioAtla's Jay M. Short, Ph.D.

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

Oct 10, 2023, 7:30 AM EDT - 1 year ago

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:00 AM EDT - 1 year ago

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

BioAtla to Participate in Upcoming Investor Conferences in August

Aug 3, 2023, 4:01 PM EDT - 1 year ago

BioAtla to Participate in Upcoming Investor Conferences in August

BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript

Aug 1, 2023, 11:18 PM EDT - 1 year ago

BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Aug 1, 2023, 4:01 PM EDT - 1 year ago

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

Jul 25, 2023, 8:00 AM EDT - 1 year ago

BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

Jun 26, 2023, 8:00 AM EDT - 1 year ago

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

BioAtla to Participate in the Jefferies Healthcare Conference

May 31, 2023, 8:00 AM EDT - 2 years ago

BioAtla to Participate in the Jefferies Healthcare Conference

BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript

May 11, 2023, 10:51 PM EDT - 2 years ago

BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

May 11, 2023, 4:01 PM EDT - 2 years ago

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress